Track Phase 2 & Phase 3 clinical trial catalysts driving biotech stock movements
DLBCL โข Fda approval
NodThera Limited is conducting a Phase 3 clinical trial evaluating R-pola-mini-CHP for the treatment of DLBCL. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Chronic Obstructive Pulmonary Disease โข Fda approval
Chiesi Farmaceutici S.p.A. is conducting a Phase 3 clinical trial evaluating Experimental: CHF6001 1600ยตg for the treatment of Chronic Obstructive Pulmonary Disease. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
PI3K and P110delta Hyperactivation Syndrome โข Fda approval
Convalife (Shanghai) Co., Ltd. is conducting a Phase 3 clinical trial evaluating CVL237 tablets for the treatment of PI3K and P110delta Hyperactivation Syndrome. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Infertility โข Fda approval
IBSA Institut Biochimique SA is conducting a Phase 3 clinical trial evaluating Progesterone-IBSA Injectable Solution for the treatment of Infertility. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Migraine โข Fda approval
Dr George Medvedev is conducting a Phase 3 clinical trial evaluating Eptinezumab for the treatment of Migraine. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Biochemical Recurrence of Malignant Neoplasm of Prostate โข Fda approval
Telix Pharmaceuticals (Innovations) Pty Limited is conducting a Phase 3 clinical trial evaluating 68Ga-PSMA-11 for the treatment of Biochemical Recurrence of Malignant Neoplasm of Prostate. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
DLBCL โข Fda approval
NodThera Limited is conducting a Phase 3 clinical trial evaluating R-pola-mini-CHP for the treatment of DLBCL. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Multiple Myeloma โข Topline data
Weill Medical College of Cornell University is conducting a Phase 2 clinical trial evaluating Daratumumab SC for the treatment of Multiple Myeloma. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Obesity โข Topline data
University of Pennsylvania is conducting a Phase 2 clinical trial evaluating Semaglutide Pen Injector for the treatment of Obesity. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Nasopharyngeal Cancer โข Topline data
National University Hospital, Singapore is conducting a Phase 2 clinical trial evaluating cisplatin and gemcitabine for the treatment of Nasopharyngeal Cancer. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Chronic Obstructive Pulmonary Disease โข Fda approval
Chiesi Farmaceutici S.p.A. is conducting a Phase 3 clinical trial evaluating Experimental: CHF6001 1600ยตg for the treatment of Chronic Obstructive Pulmonary Disease. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
PI3K and P110delta Hyperactivation Syndrome โข Fda approval
Convalife (Shanghai) Co., Ltd. is conducting a Phase 3 clinical trial evaluating CVL237 tablets for the treatment of PI3K and P110delta Hyperactivation Syndrome. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Tinnitus โข Topline data
University of Minnesota is conducting a Phase 2 clinical trial evaluating incobotulinum toxin A for the treatment of Tinnitus. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Breast Cancer โข Topline data
M.D. Anderson Cancer Center is conducting a Phase 2 clinical trial evaluating Zanidatamab for the treatment of Breast Cancer. The primary completion date is December 2025, which represents a key catalyst for the company. This trial enrolls 100 patients.
Alzheimer's Disease โข Topline data
This topline_data represents a key inflection point for Biogen Inc's BIIB080 program. Based on preclinical data and trial design, there is potential for significant stock movement upon data release.
Unresectable or Metastatic Melanoma or Advanced Solid Tumors โข Topline data
Key Phase 2 catalyst for Merck
Sign up to create watchlists, get alerts, and access detailed catalyst analysis powered by AI.